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Abstract
Background: In this study was investigate IAPs in normal human prostate (NP), benign prostatic hyperplasia (BPH),
prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma (PC), and their involvement in apoptosis/
proliferation via NF-kB (TNF-a, IL-1) stimulation.
Methods: Immunohistochemical and Western blot analyses were performed in 10 samples of normal prostates, 35
samples of BPH, 27 samples diagnosis of PIN (with low-grade PIN or high-grade PIN) and 95 samples of PC (with
low, medium or high Gleason grades).
Results: In NP, cytoplasm of epithelial cells were positive to c-IAP1/2 (80% of samples), c-IAP-2 (60%), ILP (20%),
XIAP (20%); negative to NAIP and survivin. In BPH, epithelial cells were immunostained to c-IAP1/2 (57.57%), c-IAP-2
(57.57%), ILP (66.6%), NAIP (60.6%), XIAP (27.27%), survivin (9.1%). Whereas low-grade PIN showed intermediate
results between NP and BPH; results in high-grade PIN were similar to those found in PC. In PC, epithelial cells
were immunostained to c-IAP1/2, c-IAP-2, ILP, NAIP, XIAP (no Gleason variation) and survivin (increasing with
Gleason).
Conclusions: IAPs could be involved in prostate disorder (BPH, PIN and PC) development since might be provoke
inhibition of apoptosis and subsequently cell proliferation. At the same time, different transduction pathway such
as IL-1/NIK/NF-kB or TNF/NF-kB (NIK or p38) also promotes proliferation. Inhibitions of IAPs, IL-1a and TNFa might
be a possible target for PC treatment since IAPs are the proteins that inhibited apoptosis (favour proliferation) and
IL-1a and TNFa would affect all the transduction pathway involucrate in the activation of transcription factors
related to survival or proliferation (NF-kB, Elk-1 or ATF-2).
Background
Prostate cancers are generally slow-growing malignan-
cies that are characterized by an imbalance in the rates
of cell division and cell death [1]. Classical apoptosis is
caused by the activation of caspases, a family of intracel-
lular cysteine proteases that lie in a latent state in cells
but become activated in response to a wide variety of
cell death stimuli [2]. At the present, inhibitor of apop-
tosis proteins (IAPs) inhibits at least two of the major
pathways for initiation of caspase activation: the mito-
chondrial pathway with cytochrome c; and the death
receptor pathway with the tumour necrosis factor (TNF)
family of death receptors [3,4]. TNF transduction path-
way has been described by our group in previous manu-
script [5,6].
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negative regulation of apoptosis. IAPs family comprises
eight proteins: Survivin, XIAP (ILP-1), c-IAP-1, c-IAP-2,
NAIP, ILP-2, apollon (BRUCE) and ML-IAP (LIVIN).
c-IAP-1 and c-IAP-2 proteins are broadly expressed in
normal human tissues with a cytoplasmic diffuse loca-
tion pattern. Expression of c-IAP-1 and c-IAP-2 has
been reported in several tumours such as in oesophageal
[7], colon [8], uterine cervix [9] or prostate [10]. Several
authors suggest that the expression of these proteins is
associated with biological characteristic of cancer such
as apoptosis [7] or aged-related [8].
The coding sequence of ILP-2 (IAP-like protein 2)
[11] is very similar to that of XIAP (ILP-1), with 80%
identity at the amino acid level [12]. Northern blot and
RT-PCR analysis of both embryonic and adult human
tissues reveals that ILP-2 expression is restricted to tes-
tis [13]. Overexpression of ILP-2 had no protective
effect on death induced by bax or caspase 9 [11,12].
In human adult tissues, NAIP (neuronal apoptosis-
inhibitory protein) transcripts were detected using
Northern blot analysis in placenta, liver [14,15], spleen,
lung [15], ovary or testis [16], with minimal expression
in a number of other tissues, including foetal tissues
[15]. By immunohistochemical analysis Maier et al. [16]
described that the presence of NAIP in liver, lung and
spleen is most likely due to macrophage infiltration.
Choie et al. [17] described overexpression of NAIP in
breast cancer patients with unfavourable clinical fea-
tures, suggesting that NAIP would play a role in the dis-
ease manifestation. However, little is known about the
clinical relevance of NAIP expression in breast cancer
and in our knowledge no report described the presence
in human prostate tissue.
Survivin is ubiquitously expressed in embryonic tissues
where apoptosis occurs, but is not expressed or
expressed at undetectable levels in several adult normal
tissues. Overexpresion of survivin has been reported in
several tumours such as in breast [16], colon [17], blad-
der [18], uterus [19], ovary [20], liver [21] or prostate
[10,22]. Moreover, survivin has been reported to be
expressed in some preneoplastic and/or benign lesions
such as polyps of the colon, breast adenomas and PIN
[10].
XIAP has been identified as one of the most potent
inhibitor of caspases and apoptosis [23]. XIAP overex-
pression in tumour cells has been shown to cause an
inhibitory effect on cell death besides to induce resis-
tance to chemotherapy [23,24]. Equally to survivin,
XIAP is overexpressed in precancerous PIN lesions [10].
Prostate diseases are chronic diseases that need a long
development period. The evolution of PC needs a long
period, probably due to the development of early and
later precancerous modifications and then to the
development of a clinical PC [25]. In this way, several
clinical studies suggest that prostatic intraepithelial neo-
plasia (PIN) precedes carcinoma by 10 years or more,
with low-grade PIN first emerging in men in the third
decade of life [26,27].
In our knowledge, although some studies on c-IAP-1,
c-IAP-2, XIAP and survivin have been reported, there
are no reports on ILP-2 and NAIP (in prostate in vivo
tissue), and studies on survivin are contradictory. The
aim of the present study was to investigate by immuno-
histochemical methods these six IAPs family members
in normal human prostate; their modifications in BPH,
PIN and PC; and their possible involvement in apoptosis
or proliferation via NF-kB (TNF-a and IL-1)
stimulation.
Methods
Prostates were obtained from: (a) transurethral resec-
tions from 33 men (aged from 53 to 88 years) with clini-
cal and histopathological diagnosis of BPH; (b) radical
prostatectomies from 27 men (aged from 20 to 59 years)
diagnosis of low-grade PIN (12 men) or high-grade PIN
(15 men); (c) radical prostatectomies from 95 men (aged
from 54 to 69 years) with PC of low (Gleason scores <
6, 23 men), medium (Gleason scores 7, 51 men) and
high (Gleason scores 8-10, 21 men) Gleason grades,
with and without metastasis or lymph node infiltration
a tt h et i m eo fs u r g e r y ;a n d(d) histologically normal
prostates (NP) obtained at autopsy (8-10 hours after
death) from 20 men (aged from 20 to 38 years) without
histories of reproductive, endocrine or related diseases.
Each diagnosed sample was divided into two portions;
one portion was immediately processed for immunohis-
tochemistry, while the other portion that was frozen in
liquid nitrogen and maintained at -80°C for Western
Blotting analysis. In this later portion, cryostat sections
were stained with toluidine blue to confirm histopatho-
logical diagnosis. Since PIN replace synonymous terms
including intraductal dysplasia, marked atypia, hyperpla-
sia with malignant changes or large acinal atypical
hyperplasia, the reproductibility of the diagnosis of Low
grade PIN is lack. All pathological, clinical or personal
data were anonymized and separated from any personal
identifiers. This study was made with the consent of the
patients’ relatives or their family in autopsy cases. All
the procedures followed were examined and approved
by the Principe de Asturias Hospital Ethics Committee
(reference number SAF2007-61928) and were in accor-
dance with the ethical standards of the Committee for
Human Experimentation, with the Helsinki Declaration
of 1975 (revised in 1983) and the Committee on Publi-
cation Ethics (COPE) guidelines.
The primary antibodies used were: rabbit polyclonal
antibody XIAP and c-IAP-2; mouse monoclonal
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Page 2 of 10antibody survivin; goat polyclonal antibodies ILP-2, c-
IAP-1/2 and NAIP (Santa Cruz Biotechnology, Ca,
USA). For Western blot analysis [28,29] antibodies were
diluted at 1:250 (survivin, NAIP, c-IAP-2, ILP), 1/500
(c-IAP-1/2, XIAP) and 1:10.000 chicken anti a-actin in
TBS with 5% bovine serum albumin (BSA). For immu-
nohistochemistry analysis [30,31] antibodies were diluted
at 1:75 (survivin, c-IAP-2, ILP), 1:100 (NAIP), 1/150 (c-
IAP-1/2, XIAP) in TBS.
Immunochemical procedure specificity was checked
using negative and positive controls. For negative con-
trols, tissues of each type (normal, BPH and PC) were
incubated with blocking peptides (Sta. Cruz Biotechnol-
ogy) or preimmune serum at the same immunoglobulin
concentration used for each antibody. As positive con-
trols, homogenates (for Western Blot) and histologic
sections (for immunohistochemistry) of human skin,
thymus or tonsils were incubated with the same
antibodies.
A comparative histologic quantification of immunola-
beling among the different types of prostates was per-
formed for each antibody. From each prostate, six
histologic sections were selected at random. In each sec-
tion, the staining intensity (optic density) per unit sur-
face area was measured with an automatic image
analyzer (Motic Images Advanced version 3.2, Motic
China Group Co., China) in 5 light microscopic fields
per section, using the X20 objective. Delimitation of sur-
face areas was carried out manually using the mouse of
the image analyzer. For each positively immunostained
section, one negative control section (the following in a
series of consecutive sections) was also used, and the
optic density of this control section was subtracted from
that of the stained section.
From the average values obtained (by the automatic
image analyzer) for each prostate, the means ± SD for
each prostate type (NP, BPH, PIN and PC) were calcu-
lated. The results were corroborated by two different
observers. The number of sections examined was deter-
mined by successive approaches to obtain the minimum
number required to reach the lowest SD. The statistical
significance between means of the different prostate
group samples was assessed by the one way ANOVA
test at p ≤ 0 . 0 5 ,b ym u l t i p l ep a i r w i s ec o m p a r i s o n s
(GraphPad PRISMA 3.0 computer program).
To determine whether the source of material (surgery
or autopsy) could be responsible for changes in the
immunohistochemical pattern, five prostatic biopsies
(taken because of the suspicion of prostatic disease and
their histologic study revealed a normal pattern) were
processed for immunohistochemistry. The results of the
quantitative immunohistochemical study in these biop-
sies were compared with those of autopsy prostates.
Results
Western blot analysis
Western blot analysis showed a single band for all the
antibodies studied at the corresponding molecular
weight in BPH and PC. In normal prostates (NP), only
NAIP and survivin were not detected, while immunor-
eactions for the other antibodies were found at the cor-
responding molecular weight (figure 1).
Immunohistochemistry
No immunoreaction was observed in the negative controls
incubated with pre-immune serum, or using the antibo-
dies preabsorbed with an excess of purified antigens.
No significant histologic or quantitative immunohisto-
chemical differences between the two subgroups of nor-
mal prostates (biopsies and autopsies) were observed.
Positive immunostaining to c-IAP-1/2 was observed in
the cytoplasm of epithelial cells in 80% of normal pros-
tates patients, in 57.57% of patients with BPH, 59.25% of
patients with PIN and in more 60% of PC patients
(Table 1). Optic density to c-IAP-1/2 was similar in the
four groups (NP, BPH, PIN and PC). In PC no differ-
ences were observed between the three Gleason groups.
Immunostaining to c-IAP-2 appeared in the cytoplasm
of basal (normal and BPH) or secretory (cancer) epithe-
lial cells in 60% of normal prostates (figure 2A), 57.57%
of patients with BPH (figure 2B, Table 1), 55.15% of
patients with PIN and in 40% of PC patients (figure 2C
and Table 1). Optic density was higher in PC and BPH
samples than in normal prostates. At the same time,
similar optic density was observed in BPH and PC with
low Gleason patients. The higher optic density was
found in PC with medium and high Gleason, but not
differences were observed between them.
ILP-2 always showed immunoreaction in the basal (nor-
mal, low grade PIN and BPH) or secretory (high grade
PIN and cancer) epithelial cell cytoplasm in 20% of normal
prostates (figure 2D, Table 1), 66.66% of BPH patients,
66.6% of low grade PIN, 80% of high grade PIN (figure
2E), 82.6% of cancer patients with low Gleason grade,
82.35% of cancer patients with medium Gleason grade
(figure 2F), and all cancer patients with high Gleason
grade (Table 1). Optic density was higher in PC samples
than in normal prostates and BPH. In PC group, the
higher optical density was observed in high Gleason group.
No immunoreaction to NAIP was found in normal
prostate (figure 2G) and low grade PIN (Table 2). Posi-
tive immunoreaction was observed in the cytoplasm of
epithelial cells in BPH (60.6% of patients) (figure 2H),
high grade PIN (60%) and PC (more 58%) (figure 2I,
Table 2). The highest optic density was found in PIN
(high grade) and PC but no differences were observed
between these or between three Gleason groups.
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Page 3 of 10Immunoreaction to survivin was absent in normal
prostates (figure 2J) and low grade PIN (Table 2). Cyto-
plasmic immunoreaction of epithelial cells was observed
in 9.1% of BPH (figure 2K), in 20% of high grade PIN
and 19.35% of PC patients (figure 2L and Table 2).
Optic density was higher in PC samples and high grade
P I N .A tt h es a m et i m ei nP Cg r o u p st h eh i g h e ro p t i c a l
density was found in high Gleason group.
Immunoreaction to XIAP was observed in the apical
cytoplasm of epithelial cells in 20% of normal prostates,
27.27% of BPH patients (figures 2M-N) and 25% of low
grade PIN (Table 2). In high grade PIN (33.3%) (figure 2O)
and PC (17.39% with low Gleason grade, 39.21% with med-
ium Gleason grade (figure 2P, Table 2), and 23.8% with
high Gleason grade) immunoreaction was perinuclear.
Optic density was higher in BPH than in normal prostate
and even higher in high grade PIN or PC, but no differ-
ences between PIN and PC Gleason groups were found.
All normal prostates and low grade PIN showed posi-
tive immunostaining to p-Elk-1, and this immunoreac-
tion was observed in the nuclei of basal epithelial cells
[31]. In BPH, the epithelial cells showed nuclear immu-
noreaction in 82.85% of patients and cytoplasmic immu-
noreaction in 14.28% of patients [31]. In high grade
PIN, the epithelial cells showed nuclear immunoreaction
in 40% of patients and cytoplasmic immunoreaction in
60% of patients. In PC, immunoreaction was nuclear in
most of 33% of patients and cytoplasmic in most of
66.6% patients (Table 3). The highest optic density was
detected in PC and High grade PIN samples (Table 3)
[31].
All normal prostates and low grade PIN showed
immunoreaction to p-ATF-2 in the nuclei of basal
epithelial cells (Table 3). In BPH, the immunoreaction
was found in the nucleus of epithelial cells in 45.71% of
patients [31]. In PC and high grade Gleason,
Figure 1 Western blot analysis. Western blot analysis of c-IAP-1/2, c-IAP-2, ILP, NAIP, Survivin, XIAP and a-actin after 15% polyacrilamide gel
electrophoresis. NP: normal prostate. BPH: benign prostate hyperplasia. PC: prostate carcinoma. The lanes showing a band correspond to a
positively stained prostate of each group.
Table 1 Percentages of patients showing positive immunohistochemical reactions to c-IAP-2, c-IAP-1/2 and ILP in
normal prostate (NP), benign prostatic hyperplasia (BPH), prostatic carcinoma (PC) and average optical densities of
immunostaining in positive patients.
c-IAP-1/2 c-IAP-2 ILP
Prostates (no.) Positive cases (%) Optical density Positive cases (%) Optical density Positive cases (%) Optical density
Normal (20) 80 19.64 ± 1.06 60 8.94 ± 0.61
a 20 5.39 ± 1.18
a
BPH (33) 57.57 18.36 ± 3.29 57.57 14.30 ± 1.2
b 66.6 17.91 ± 1.44
b
PIN
Low grade PIN (12) 58.37 18.04 ± 1.29 66.6 9.83 ± 0.9
a 66.6 7.26 ± 1.01
a
High grade PIN (15) 60 18.91 ± 1.69 46.6 15.33 ± 1.52
b 80 23.14 ± 1.49
c
PC
Low Gleason (23) 60.86 19.12 ± 1.63 39.13 14.44 ± 1.56
b 82.6 23.87 ± 1.85
c
Medium Gleason (51) 70.58 18.36 ± 2.38 39.21 19.08 ± 2.16
c 82.35 23.79 ± 2.11
c
High Gleason (21) 57.14 18.07 ± 1.94 42.85 18.45 ± 1.75
c 100 27.78 ± 1.91
d
Average optical densities were evaluated only in patients showing positive immunoreactions. Statistical analysis refers to each antibody separately. Values
denoted by different superscripts are significantly different from each other. Significance was determined by the one way ANOVA test at p ≤ 0.05, by multiple
pairwise comparisons (GraphPad PRISMA 3.0 computer program).
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Page 4 of 10Figure 2 Immunohistochemical analysis. c-IAP-2 immunostaining appeared in the basal epithelial cells of normal (A) and BPH (B), whereas
appeared in secretory epithelial cell of PC (C) samples. The cytoplasm of basal (normal and BPH) and secretory (cancer) epithelial cells presented
positive immunoreaction to ILP in normal (D), high grade prostatic intraepithelial neoplasia (PIN) (E) and PC samples (F). No immunoreaction was
found to NAIP in normal prostate (G) but was localized in the cytoplasm of epithelial cells in BPH (H) and PC (I) samples. Normal prostate (J) was
negative to Survivin whereas immunoreaction was found in epithelial cells of BPH (K) and PC (L) samples. Immunoreaction to XIAP was observed
in the apical cytoplasm of epithelial cells in BPH patients (Figs. M-N) whereas was perinuclear in high grade prostatic intraepithelial neoplasia
(PIN) and PC (P) samples. Scale bars: 10 μm (O), 20 μm (B, E, H) and 30 μm (A, C-D, F-G, I-N, P).
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Page 5 of 10immunostaining was nuclear in most of 14% of patients
and cytoplasmic in most of 50% of patients (Table 3).
The highest optic density was found in PC and high
grade Gleason samples [31].
Scanty immunoreaction to NF-kB/p50 was localized in
the cytoplasm of epithelial cells in 60% of normal pros-
tate, 58.3% of low-grade PIN [5] and 100% of BPH
patients. In PC, immunostaining was more intense
(higher optic density) and appeared in the cytoplasm of
epithelial cells in 80.9% of low Gleason grade, 4.1% of
medium Gleason and 100% of high Gleason, and also in
the nucleus of epithelial cells in 30.1% of patients with
low Gleason, 41.2% with medium Gleason, and 47.6% of
high Gleason (Table 3) [5]. Similar data were observed
in high-grade PIN, where immunoreaction was found in
cytoplasm (86.6% of patients) and nucleus (26.6% of
patients) of epithelial cells (Table 3) [5].
No immunoreaction to NF-kB/p65 was observed in
normal prostates and low-grade PIN samples [5]. In
BPH immunoreaction appeared in cytoplasm of epithe-
lial cells in 71.4% of cases. In PIN, cytoplasmic (93.3%)
and nuclear (13.3%) immunostainings were found in
epithelial cells. In PC cytoplasmic immunostaining was
observed in 100% of low Gleason grade, 92.1% of med-
ium Gleason and 80.9% of high Gleason, and nuclear
immunostaining was found in 19% of low Gleason
grade, 45.1% of medium Gleason and 71.4% of high
Gleason (Table 3) [5]. Optical density was higher in PC
and high-grade PIN patients than in BPH. No differ-
ences in optic densities regarding location (cytoplasm or
nucleus) or Gleason grade were found (Table 3) [5].
Discussion
The processes of both cell survival and cell death have
involved highly regulated signalling pathways that are cur-
rently the subject of intense investigation. The rates of
epithelial cell growth and death in adult normal prostate
glands are in equilibrium [1]. The signalling pathways that
lead to apoptosis or cell growth are beginning to be
defined, and a number of proteins have been identified.
We used immunohistochemical analysis in order to
know the percentage of positive patients, the location and
the expression of each protein studied. So, the immuno-
histochemical analysis data are used to obtain the optical
density data as we described in methods sections.
In normal prostate, we observed immunoexpressions
to c-IAP-1/2, c-IAP-2, ILP-2, XIAP and NF-kB (p-50) in
the cytoplasm of epithelial cells; p-Elk-1 and p-ATF-2 in
the epithelial cell nuclei; but no immunoreaction to
NAIP, survivin and NF-kB (p-65) were found (see Table
3). Several publications described survivin expression in
normal tissues [26]. However, other authors have been
reported that immunoexpression is not detected by
immunohistochemistry in normal tissues [27] and has
been only described by RT-PCR [25]. Vischioni et al.
[28] also described cytoplasmic localization to c-IAP-1/
2, c-IAP-2 and XIAP in normal prostate. The cytoplas-
mic localization described might be related to their
binding to plasma membrane receptors such as the
bone morphogenic protein type I receptors in the case
of XIAP [32] or the tumour necrosis factor-receptor
complexes in the case of c-IAP-1 and c-IAP-2. In low
grade PIN we obtained similar results to those described
in normal prostates samples. These observations could
be suggest that expressions of these IAPs in normal
prostate and PIN could be promoted the equilibrium
between proliferation and apoptosis described in normal
tissues. Since these IAPs were found in considerably
amounts in BPH, high grade PIN and PC specimens,
evaluation of these products can be helpful to discrimi-
nate between prostatic tissues that are normal and those
subjected to pathologic proliferative processes.
Table 2 Percentages of patients showing positive immunohistochemical reactions to NAIP, Survivin and XIAP in
normal prostate (NP), benign prostatic hyperplasia (BPH), prostatic carcinoma (PC) average optical densities of
immunostaining in positive patients.
NAIP SURVIVIN XIAP
Prostates (no.) Positive cases (%) Optical density Positive cases (%) Optical density Positive cases (%) Optical density
Normal (20) 0
— 0 — 20 6.96 ± 1.6
a
BPH (35) 60.6 11.23 ± 2.9
a 9.1 8.4 ± 1.51
a 27.27 13.42 ± 0.59
b
PIN
Low grade PIN (12) 0 —— 0 — 25 9.6 ± 1.21
c
High grade PIN (15) 60 18.49 ± 2.02
b 20 17.46 ± 1.57
b 33.3 16.93 ± 1.73
d
PC
Low Gleason (21) 56.52 17.4 ± 1.96
b 21.7 17.48 ± 1.53
b 17.39 17.79 ± 1.55
d
Medium Gleason (51) 58.82 18.25 ± 2.02
b 13.72 17.66 ± 1.6
b 39.21 16.64 ± 1.31
d
High Gleason (21) 66.6 17.28 ± 2.46
b 28.57 21.59 ± 1.35
c 23.8 16.38 ± 1.03
d
Average optical densities were evaluated only in patients showing positive immunoreactions. Statistical analysis refers to each antibody separately. Values
denoted by different superscripts are significantly different from each other. Significance was determined by the one way ANOVA test at p ≤ 0.05, by multiple
pairwise comparisons (GraphPad PRISMA 3.0 computer program).
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c-IAP-2, ILP-2, NAIP, survivin, XIAP, p-Elk-1, p-ATF-2
and NF-kB (p50 and p65). Similar results have been
described by other authors to survivin [33]. These IAPs
that are increased in BPH perhaps might be provoked
the lower apoptosis index described in this benign
pathology. This agrees with the high levels of other fac-
tor relate with proliferation or anti-apoptotic factors
( s u c ha sN F - k B ,b c l - 2 ,m c l - 1 ,p 2 1o rR b )a n dr e p o r t e d
in the same patients used in this study [4,30,34]. De
Miguel et al. [35] in the same samples used in this
study, described that the proliferation index (measured
by Ki-27 nuclear antigen) increased respect to that of
the normal prostate, but the apoptotic index (measured
by TUNEL) was similar than normal and, therefore, the
equilibrium is displaced toward proliferation. These data
could be suggests that an active stimulation of cell pro-
liferation and survival occurs.
In PC, we described that the percentage of patients
positives to all the IAPs family members studied is simi-
l a r( c - I A P 1 / 2 ,N A I Po rX I A P ) ,m a j o r( I L P - 2 ,S u r v i v i n )
or minor (c-IAP-2) than in BPH. NF-kB (p50 and p65)
changes the location from the cytoplasm to the nucleus
[5] whereas p-Elk-1 and p-ATF-2 changes the location
from the nucleus to the cytoplasm in most of the PC
patients examined [31]. The nuclear translocation of
NF-kB activates target genes involved in carcinogenesis,
such as IAPs [5]. Cytoplasm location to p-Elk-1 and p-
ATF-2 could be mutant form that present altered func-
tions and may be associated with the prostate cancer
development [31]. In the other hand, optical density is
more elevated in PC than in BPH (c-IAP-2, ILP, NAIP,
Survivin, XIAP, NF-kB, p-Elk-1 and p-ATF-2); but only
survivin and NF-kB increased with Gleason grade. We
observed that immunoreactions were cytoplasmic (c-
IAP-1/2, c-IAP-2, ILP, NAIP and survivin) or perinuc-
lear (XIAP). The percentages of patients as well as the
optical densities observed in high grade PIN have been
similar to those observed in PC. These data also have
been obtained by others authors. Similar localization to
c-IAP-1, c-IAP-2 and XIAP in PC3 cells was described
by McEleny et al. [36] in in vitro studies, suggesting that
Table 3 Percentages of patients showing positive immunohistochemical reactions to p-ELK-1, ATF-2 [31], p50 and p65
[5] in normal prostate (NP), benign prostatic hyperplasia (BPH) and prostatic carcinoma (PC) and average optical
densities of immunostaining in positive patients.
p-ELK-1 p-ATF-2 p50 p65
Prostates (no.) Positive
cases (%)
Optical
density
Positive
cases (%)
Optical
density
Positive
cases (%)
Optical
density
Positive
cases (%)
Optical
density
Normal (20) 100 2.41 ± 0.9
a 100 3.34 ± 0.83
a 60 7.88 ± 2.4* 0
BPH (35)
Cytoplasm 14.28 9.42 ± 5.13* 100 18.6 ± 1.72
# 71.4 9.08 ± 3.23*
Nucleus 82.85 10.52 ± 2.56
b 45.71 5.25 ± 2.16
a
PIN
Low grade
PIN (12)
100 3.22 ± 0.7
a 100 4.32 ± 1.09* 58.3 15.32 ± 2.00
# 0
High grade
PIN (15)
Cytoplasm 60 17.35 ± 1.45
# 53.3 13.35 ± 1.78
# 86.6 27.51 ± 2.79
§ 93.3 30.17 ± 3.08
#
Nucleus 40 18.27 ± 2.31
c 26.6 12.31 ± 4.21
b 26.6 28.76 ± 3.31
a 13.3 29.77 ± 2.13
a
PC
Low Gleason (21)
Cytoplasm 66.6 19.62 ± 5.64
# 61.9 12.68 ± 3.28
# 80.9 28.01 ± 2.25
§ 100 23.8 ± 2.93
§
Nucleus 42.85 18.65 ± 3.4
c 23.8 10.58 ± 1.2
b 30.1 32.08 ± 2.96
a 19 28.34 ± 2.04
a
Medium
Gleason (51)
Cytoplasm 72.54 17.75 ± 4.54
# 68.62 11.75 ± 3.45
# 94.1 29.17 ± 1.22
§ 92.1 29.09 ± 1.90
#
Nucleus 37.25 17.23 ± 3.56
c 19.6 9.56 ± 3.87
b 41.2 33.82 ± 4.07
a 45.1 34.91 ± 4.32
b
High Gleason (21)
Cytoplasm 85.71 19.76 ± 4.78
# 76.19 12.98 ± 5.11
# 100 39.37 ± 4.15
¥ 80.9 36.71 ± 2.18
¥
Nucleus 33.3 18.76 ± 3.87
c 14.28 13.43 ± 3.56
b 47.6 41.26 ± 2.31
b 71.4 46.56 ± 1.20
c
Average optical densities were evaluated only in patients showing positive immunoreactions. Statistical analysis refers to each antibody separately. Statistical
analysis also separated cytoplasmic (symbol superscripts) and nuclear (letter superscripts) values. Values denoted by different superscripts are significantly
different from each other. Significance was determined by the one way ANOVA test at p ≤ 0.05, by multiple pairwise comparisons (GraphPad PRISMA 3.0
computer program).
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Page 7 of 10IAP may be an important contribution to apoptotic
resistance in patients with prostate cancer. Krajewska et
al. [10] by immunohistochemical analysis of prostate
tumour tissues reveals cancer-specific elevations in the
expression of cIAP1, cIAP2, survivin and XIAP; but
immunostaining data did not correlate with Gleason
scores or PSA. Vischioni et al. [28], also described cyto-
plasmic localization to XIAP. In several prostate cancer
cell lines (PC3 and LNCaP), the expression of XIAP was
perinuclear [36]. XIAP overexpression in tumour cells
has been shown to cause an inhibitory effect on cell
death induced by a variety of apoptotic stimuli [23]. In
prostate adenocarcinoma, survivin has been shown to be
overexpressed in an elevated proportion of patients.
Nevertheless, results about correlations among survivin
expression and both clinical and pathological features
are contradictory [10,36-40]. An important finding is the
involvement of survivin with resistance to antiandrogen
therapy for prostate cancer [39]. At the present and in
our knowledge, this is the first manuscript that describes
ILP-2 and NAIP in human prostate in vivo tissue. In
breast cancer survivin and NAIP overexpression has
been associated in unfavourable clinical features [17]. In
our data survivin (but not NAIP) only was increased in
high Gleason grade. At the same time, we observed dif-
ferent localization to NAIP in cancer (compared to
BPH) since not all epithelial cells were positives.
In general, IAPs have been shown to protect cells
f r o maw i d er a n g eo fa p o p t o t i ct r i g g e r si n c l u d i n gF a s
ligation, bax, activated caspases, cytochrome C, TNFa,
some chemotherapeutic agents viral infection and radia-
tion [36]. Elevations in the expression of several IAPs
occur as a frequent and early event in the etiology of
prostate cancer. Activation of NF-kB (translocation to
the nucleus) promotes cell growth and proliferation in
prostate cancer cells by regulating the expression of c-
myc, cyclin D1 or IL-6 [29,40]; but also by the up-regu-
lation of the expression of several anti-apoptotic pro-
teins, including the inhibitor of apoptosis proteins
(IAPs) [29]. Recent report [41,42] described IAPs family
as downstream targets of activated NF-kB. In previous
reports made in the same samples used here we
described that in PC, the indexes of proliferation (by Ki-
67 nuclear antigen and PCNA) and apoptosis (by
TUNEL) were higher than in NP and BPH samples [35].
Nuñez et al. [5] using the same PC samples that we use
in this study, also was observed increased levels of NF-
kB, concluded that NF-kB is a new predictive marker of
prostate cancer. At the same time activation to NF-kB
together activation of other transcription factors, also
studied in this patients by our group, such ATF-2 and
Elk-1 [31] (related with enhanced cell proliferation and
survival) might be due the overexpression of several
components of the IL-1/NIK/NF-kB or TNF/NF-kB
(NIK or p38) pathways [5]. At the same time activation
of ATF-2, Elk-1 and NF-kB also are the consequence of
p38 pathway (IL-1/p38 or TNF-p38) activation [31].
Conclusions
In summary, it is reasonable to speculate that IAPs could
be involved in prostate disorder (BPH, PIN and PC)
development since might be provoke inhibition of apop-
tosis. So, the attempt of these proteins to respond against
proliferation is insufficient. At the same time, different
transduction pathway such as IL-1/NIK/NF-kB or TNF/
NF-kB (NIK or p38) also promotes proliferation by acti-
vation of several transcription factors as NF-kB but also
Elk-1 or ATF-2. Interpretation of these data suggests
that, in prostate cancer, there are a higher number of fac-
tors relate with activation of mitogenic signaling cas-
cades. In order to search a dominant target for therapy, it
should be taken into account that PC is a heterogeneous
disease in which multiple transduction pathways may
interact in the uncontrolled apoptosis/cell proliferation.
Inhibitions of IAPs, IL-1a and TNFa might be a possible
target for PC treatment since IAPs are the proteins that
inhibited apoptosis (favour proliferation) and IL-1a and
TNFa would affect all the transduction pathway involu-
crate in the activation of transcription factors related to
survival or proliferation (NF-kB, Elk-1 or ATF-2).
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